Panels include Structuring Your Life Sciences Transaction - Licensing vs. M&A vs. Asset Sale and Key Issues for Your Biopharma Licensing Deal - IP, Scientific, and More
Learning Outcomes:
- Deal trends
- Considerations when structuring your deal
- Should you do an M&A vs. license vs. asset sale – considerations for deal
- Strategies for doing a deal with big pharma
- What does big pharma look for in a deal structure?
- Is licensing a way to an M&A deal with big pharma?
- Key non-economic issues for your biopharma licensing deal
- IP – how does big pharma diligence it, and how can a biotech satisfy a big pharma
- Scientific rigor – How does a big pharma evaluate your science?
- How do these key issues play into your license agreement?
- How do you run an efficient and productive diligence process?
- How should you time your licensing deal with your data readout?
Read more & register!